



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.
Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.
E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | URL : www.ishitadrugs.com

Phone : +91 7226995613/14/15 | +91 79 4002 3839

Date: 12.11.2024

To,
The Department of Corporate Services,
BSE Limited.
Floor No. 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

Scrip Code: 524400

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on 12th November, 2024

Pursuant to the regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e. 12th November, 2024 have

1. Approved the Unaudited Financial Results of the Company for the quarter ended 30th September, 2024. The Limited Review Report issued by the Statutory Auditors of the Company enclosed herewith.
2. Acceptance of the Resignation received from Mr. Govind Madanlal Gupta [DIN: 00052690], non-executive independent Director of the Company, due to his pre-occupation and other professional commitments, with effect from close of business hours on 12th November, 2024.

There are no other material reasons for his resignation other than those mentioned in his resignation letter.

The details required in terms of regulation 30 read with Schedule III- Para A(7B) of Part A of the Listing regulations and SEBI Circulars issued in this regard, are given in **Annexure - I**. The letter of resignation received from Mr. Govind Madanlal Gupta is enclosed herewith in **Annexure - II**.

The composition of Board of Directors of the Company is in compliance with the requirements prescribed under the Companies Act, 2013 and SEBI Listing Regulations.

"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054
D & B D-U-N-S Number - 65-018-0359



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad

E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | URL : www.ishitadrugs.com

Phone : +91 7226995613/14/15 | +91 79 4002 3839

The meeting was commenced at 06:00 p.m. and concluded at 07 : 00 p.m.

Please take the above details on your records.

Thanking You.

For, Ishita Drugs and Industries Limited

Jagdish Agrawal
Managing Director

"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359

Date: 12/11/2024

To,
The Board of Directors,
Ishita Drugs & Industries Limited,
Ahmedabad.

LIMITED REVIEW REPORT

We have reviewed the accompanying of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LIMITED** for the period **01 Jul 2024 to 30 Sep 2024**. (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of **Interim financial information performed by the Independent auditor of the entity issued by the Institute of Chartered Accountants of India**. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribe under section 133 of companies Act, 2013 read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
JAYMIN SHAH & ASSOCIATES



CA Mayank Sancheti

M No. :170863

Date: 12/11/2024

Place: Ahmedabad

UDIN: 24170863BKARSA4306

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com


Contact: +91 7226995613/14/15

Unaudited Financial Results for the Quarter and Half year Ended September 30, 2024

Amount in Lacs except Per Share data


		Quarter Ended			Half Year Ended		Year Ended
		3 Months Ended	3 Months Ended	3 Months Ended	6 Months Ended	6 Months Ended	12 Months Ended
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
		30-Sep-24	30-Jun-24	30-Sep-23	30-Sep-24	30-Sep-23	31-Mar-24
1	INCOME						
	Revenue from Operations	327.42	302.76	439.50	630.19	748.13	1518.76
	Other Income	5.05	5.83	9.58	10.88	17.01	28.02
	Total Income	332.47	308.59	449.08	641.07	765.14	1546.78
2	EXPENSES						
(a)	Cost of Material Consumed	218.39	185.21	314.49	403.60	538.16	1137.46
(b)	Purchase of Stock-In-Trade	0.00	4.30	5.40	4.30	5.40	6.40
(c)	Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	5.02	18.07	9.61	23.09	-2.45	-14.51
(d)	Employee Benefit Expense	32.44	34.39	34.60	66.83	65.69	133.89
(e)	Finance Cost	0.33	0.78	0.69	1.11	3.30	8.98
(f)	Depreciation, Depletion and Amortisation Expense	2.79	2.79	3.23	5.58	6.66	11.17
(g)	Other Expense	47.66	43.41	53.55	91.07	102.62	164.67
	Total Other Expenses	47.66	43.41	53.55	91.07	102.62	164.67
	Total Expenses	306.63	288.96	421.57	595.59	719.39	1448.06
3	Total Profit before Exceptional Items and Tax	25.84	19.64	27.51	45.48	45.75	98.73
4	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
5	Total Profit before Tax	25.84	19.64	27.51	45.48	45.75	98.73
6	Tax Expense						
7	Current Tax	6.35	4.90	6.50	11.25	11.00	24.00
8	Deferred Tax	0.00	0.00	0.00	0.00	0.00	-0.12
9	Total Tax Expenses	6.35	4.90	6.50	11.25	11.00	23.88
10	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00
11	Net Profit Loss for the period from continuing operations	19.49	14.74	21.01	34.23	34.75	74.85
12	Profit / (Loss) from discontinued operations before tax	0.00	0.00	0.00	0.00	0.00	0.00
13	Tax Expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
14	Net Profit / (Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0.00	0.00

Jaydevi Agrawal



15	Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00	0.00
16	Total Profit / (Loss) for the period	19.49	14.74	21.01	34.23	34.75	74.85
17	Other Comprehensive Income net of Taxes	0.00	0.00	0.00	0.00	0.00	0.00
18	Total Comprehensive Income for the Period	19.49	14.74	21.01	34.23	34.75	74.85
19	Total profit or loss attributable to						
	Profit or loss, attributable to owners of parents	0.00	0.00	0.00	0.00	0.00	0.00
	Total Profit or loss, attributable to non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00
20	Total comprehensive income for the period attributable to						
	Comprehensive Income for the period attributable to the owners of parents	0.00	0.00	0.00	0.00	0.00	0.00
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00
21	Details of Equity Share Capital						
	Paid-Up Equity Share Capital	299.03	299.03	299.03	299.03	299.03	299.03
	Face Value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00	10.00
22	Details of Debt Securities						
	Paid-Up Debt Capital	0.00	0.00	0.00	0.00	0.00	0.00
	Face Value of Debt Securities	0.00	0.00	0.00	0.00	0.00	0.00
23	Reserves Excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00	0.00
24	Debenture Redemption Reserve	0.00	0.00	0.00	0.00	0.00	0.00
25	Earnings Per Share						
(i)	Earnings Per Share for continuing operations						
	Basic Earnings / (Loss) per share from continuing operations	0.65	0.49	0.70	1.14	1.16	2.50
	Diluted Earnings / (Loss) per share from continuing operations	0.65	0.49	0.70	1.14	1.16	2.50
(ii)	Earnings Per Share for discontinued operations						
	Basic Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
	Diluted Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
(iii)	Earnings per Equity Share						
	Basic Earnings / (Loss) per share from continuing and discontinued operations	0.65	0.49	0.70	1.14	1.16	2.50
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	0.65	0.49	0.70	1.14	1.16	2.50
26	Debt Equity Ratio	--	--	--			--
27	Debt Service Coverage Ratio	--	--	--			--
28	Interest Service Coverage Ratio	--	--	--			--

Jaydevi



NOTES

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on November 12, 2024.
2. The Limited Review of the results has been completed by the Statutory Auditors of the Company.
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
4. The financial results for the quarter and half year ended 30th September, 2024 are also Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
6. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, **ISHITA DRUGS AND INDUSTRIES LIMITED**



Jagdish Agrawal

JAGDISH AGRAWAL

MANAGING DIRECTOR

DIN: 01031687

Place **Ahmedabad**

Date **12-Nov-24**

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
Ahmedabad – 382170


Website: www.ishitadrugs.com

Contact: +91 7226995613/14/15

Statement of Assets and Liabilities

Amount in Lakhs

Particulars	Half Year Ended	Previous Year Ended
	6 Months Ended	12 Months Ended
	Unaudited	Audited
	30-Sep-24	31-Mar-24
ASSETS		
1 Non-current assets		
Property, plant and equipment	73.10	80.46
Capital work-in-progress		
Investment property		
Goodwill		
Other intangible assets		
Intangible assets under development		
Biological assets other than bearer plants		
Investments accounted for using equity method		
Non-current financial assets	73.10	80.46
Non-current investments	33.41	27.15
Trade receivables, non-current		
Loans, non-current		
Other non-current financial assets	7.34	7.56
Total Non-current financial assets	40.75	34.71
Deferred tax assets (net)		
Other non-current assets		
Total Non-current Assets	113.84	115.17
2 Current assets		
Inventories	156.14	106.42
Current financial assets		
Current investments	426.51	306.51
Trade receivables, current	165.52	69.90
Cash and cash equivalents	322.94	182.53
Bank balance other than cash and cash equivalents	309.88	298.45
Loans, current	0.00	0.12
Other current financial assets	0.30	1.77
Total current financial assets	1225.15	859.28
Current tax assets (net)		
Other current assets (DEPOSITS)		
Total Current Assets	1381.29	965.70
3 Non-current assets classified as held for sale		
4 Regulatory deferral account debit balances and related deferred tax Assets		
TOTAL ASSETS	1495.13	1080.87



EQUITIES AND LIABILITIES			
1	Equity		
	Equity attributable to owners of Parent		
	Equity share capital	299.03	299.03
	Other equity	727.35	693.12
	Total Equity attributable to owners of Parent	1026.38	992.15
	Non controlling interest		
	Total Equity	1026.38	992.15
2	Liabilities		
	Non-current liabilities		
	Non-current financial liabilities		
	Borrowing, non-current		
	Trade payables, non-current		
	Other non-current financial liabilities		
	Total Non-current financial liabilities	0.00	0.00
	Provisions, non-current		
	Deferred tax liabilities (net)	1.99	1.99
	Deferred government grants, Non-current Other non-current liabilities		
	Total Non-current liabilities	1.99	1.99
	Current liabilities		
	Current financial liabilities		
	Borrowing, current	211.23	0.00
	Trade payables, current	183.57	45.82
	Other current financial liabilities	0.00	0.00
	Total current financial liabilities	394.80	45.82
	Other current liabilities	40.34	14.95
	Provisions, current	12.09	12.32
	Current tax liabilities (Net)	19.53	13.63
	Deferred government grants, Current		
	Total current liabilities	71.96	86.73
3	Liabilities directly associated with assets in disposal group classified as held for sale		
4	Regulatory deferral account credit balances and related deferred tax		
	Total Liabilities	468.75	88.72
	Total Equity and Liabilities	1495.13	1080.87

For, ISHITA DRUGS AND INDUSTRIES LIMITED



Jagdish Agrawal

JAGDISH AGRAWAL

MANAGING DIRECTOR

DIN: 01031687

Place Ahmedabad

Date 12-Nov-24

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613/14/15


AUDITED CASH FLOW STATEMENT

Sr. No.	Perticulers	Unaudited Halfyear Ended 30.09.2024 Rs. In Lakhs	Audited Year Ended 31.03.2024 Rs. In Lakhs
(A)	Cash flow from operating activities :		
	Profit before tax	45.48	98.73
	Add : Depreciation	5.58	11.17
	Interest & Other financial charges	1.11	8.98
	Loss on sale of fixed assets	0.17	0.00
	Less : Interest received	10.71	18.06
	Dividend received	0.01	0.09
	Income from Investments	0.00	9.87
	Operating profit before change in working capital	41.62	90.85
	Add : Trade Debtors	(95.62)	110.13
	Decrease/(Increase) in Inventory	(49.71)	53.41
	Decrease/(Increase) in Loans and advances	1.82	20.22
	Less : Provision for Taxation	11.25	24.00
	Decrease/(Increase) Shore Term Provision	(25.16)	5.44
	Decrease/(Increase) Trade Creditors, Current liabilities & Provisions	(143.65)	33.09
	Net cash generated from operating activities (A)	55.65	212.08
(B)	Cash inflow from investing activities :		
	Add : Investment sold / (purchased)	(126.26)	5.74
	Dividend received	0.01	0.09
	Income from Investments	0.00	9.87
	Profit on sale of fixed assets	0.00	0.00
	Less : Capital work in progress	0.00	0.00
	Loss on sale of fixed assets	0.17	0.00
	Less : Investment in fixed assets	(1.78)	2.68
	Net cash generated from investing activities (B)	(124.47)	13.03
(C)	Cash flow from financial activities :		
	Add : Gains of settlement of debts	0.00	0.00
	Add : Interest received	10.71	18.06
	Borrowings	211.23	(96.04)
	Less : Repayment of borrowings	0.00	0.00
	Less : Interest & Other financial charges	1.11	8.98
	Net cash generated from financial activities (C)	220.83	(86.95)
	Net Increase/(decrease) in Cash & Cash Equivalents (A+B+C)	151.85	138.15
	Opening balance of Cash and cash equivalents	480.98	342.83
	Closing balance of Cash and cash equivalents	632.83	480.98
	Net Increase/(decrease) in Cash & Cash Equivalents	151.85	138.15

Note : Figures in bracket indicate negative value

Correctly extracted from Audited accounts of the Company

For, ISHITA DRUGS AND INDUSTRIES LIMITED



Jagdish Agrawal

JAGDISH AGRAWAL
MANAGING DIRECTOR
DIN: 01031687

Place **Ahmedabad**
Date **12-Nov-24**



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.

E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | URL : www.ishitadrugs.com

Phone : +91 7226995613/14/15 | +91 79 4002 3839

Annexure - I

Information as required under Regulation 30 - of SEBI

(Listing Obligations and Disclosure Requirements) Regulations 2015

Sr. No.	Particulars	Details
1.	Reasons for Change viz. appointment, resignation, removal, otherwise;	Resignation of Mr. Govind Madanlal Gupta [DIN: 00052690], Non-executive Independent Director of the Company with effect from the close of business hours on 12 th November, 2024.
2.	Date of Appointment/Cessation (as applicable) & Term of appointment	Cessation with effect from close of business hours on 12 th November, 2024.
3.	Brief Profile (in case of Appointment)	Not Applicable
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable
5.	Other Directorships / Memberships (in listed entities in case of resignation of independent director)	Indusa Facility Services LLP
6.	Letter of resignation along with detailed reason for resignation	Enclosed herewith in Annexure II
7.	The Independent director shall, along with the detailed reasons, also provide a confirmation that there are no other material reasons other than those provided.	Mr. Govind Madanlal Gupta has confirmed that there are no material reasons for his resignation other than those mentioned in his resignation letter.

"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359

Annexure - II

Date: 12.11.2024

**The Board of Directors of
Ishita Drugs and Industries Limited**

Survey No 179/1,
Vasna-Iyava, Taluka Sanand,
Ahmedabad, Gujarat, India, 382210

Dear Sir/Madam,

Subject: Resignation as an Independent Director of the Company

This is to inform the Board that due to my pre-occupation and other professional commitments hereby tender my resignation as an Independent Director of the Company with effect from close of business hours on 12th November, 2024.


I hereby confirm that there are no other material reasons for my resignation other than those mentioned above.

I take this opportunity to thank the Board and other Committee members for the support extended to me during my tenure as a Non- Executive Independent Director of the Company.

Kindly acknowledgement the receipt of this resignation letter and arrange to submit the necessary forms with the Registrar of Companies and Stock Exchange.

Thanking You.

Yours Faithfully,



GOVIND MADANLAL GUPTA

Director

DIN: 00052690